Bristol-Myers Squibb Shares Outstanding 2006-2018 | BMY

Bristol-Myers Squibb shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Bristol-Myers Squibb shares outstanding for the quarter ending September 30, 2018 were 1.636B, a 0.55% decline year-over-year.
  • Bristol-Myers Squibb 2017 shares outstanding were 1.652B, a 1.67% decline from 2016.
  • Bristol-Myers Squibb 2016 shares outstanding were 1.68B, a 0.06% increase from 2015.
  • Bristol-Myers Squibb 2015 shares outstanding were 1.679B, a 0.54% increase from 2014.
Bristol-Myers Squibb Annual Shares Outstanding
(Millions of Shares)
2017 1,652
2016 1,680
2015 1,679
2014 1,670
2013 1,662
2012 1,688
2011 1,717
2010 1,727
2009 1,978
2008 1,999
2007 1,977
2006 1,963
2005 1,983
Bristol-Myers Squibb Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 1,636
Q2 2018 1,636
Q1 2018 1,640
Q4 2017 1,652
Q3 2017 1,645
Q2 2017 1,650
Q1 2017 1,671
Q4 2016 1,680
Q3 2016 1,679
Q2 2016 1,679
Q1 2016 1,680
Q4 2015 1,679
Q3 2015 1,678
Q2 2015 1,667
Q1 2015 1,676
Q4 2014 1,670
Q3 2014 1,670
Q2 2014 1,669
Q1 2014 1,666
Q4 2013 1,662
Q3 2013 1,662
Q2 2013 1,660
Q1 2013 1,655
Q4 2012 1,688
Q3 2012 1,666
Q2 2012 1,701
Q1 2012 1,706
Q4 2011 1,717
Q3 2011 1,715
Q2 2011 1,722
Q1 2011 1,714
Q4 2010 1,727
Q3 2010 1,726
Q2 2010 1,728
Q1 2010 1,725
Q4 2009 1,978
Q3 2009 1,984
Q2 2009 1,983
Q1 2009 1,981
Q4 2008 1,999
Q3 2008 2,002
Q2 2008 2,006
Q1 2008 2,008
Q4 2007 1,977
Q3 2007 2,012
Q2 2007 2,006
Q1 2007 1,997
Q4 2006 1,963
Q3 2006 1,992
Q2 2006 1,994
Q1 2006 1,988
Q4 2005 1,983
Q3 2005 1,984
Q2 2005 1,984
Q1 2005 1,981
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $86.637B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.174B 18.29
Pfizer (PFE) United States $261.450B 14.74
Merck (MRK) United States $206.852B 17.92
Novartis AG (NVS) Switzerland $201.155B 17.24
AbbVie (ABBV) United States $130.807B 11.61
Eli Lilly (LLY) United States $120.318B 21.15
Novo Nordisk (NVO) Denmark $110.887B 18.01
Sanofi (SNY) France $109.052B 13.50
AstraZeneca (AZN) United Kingdom $96.706B 12.01
GlaxoSmithKline (GSK) United Kingdom $92.502B 12.43